|
| 
Research Areas
|
OvaCheck®, Correlogic’s blood test for detection of ovarian cancer, is our test nearest to commercial availability. The test is currently undergoing clinical trials in anticipation of FDA review.
More > |
|
Correlogic’s second diagnostic test will be its blood test for colorectal cancer. Work is underway on a blood test for detection of colon cancer and potentially for colon adenomas (precancerous polyps).
More > |
|
Correlogic is conducting research to develop MammoCheck®, a blood test for detection of breast cancer. MammoCheck will be intended initially as a diagnostic tool following a suspicious mammogram.
More > |
|
ProstaCheck® Correlogic’s blood test for prostate cancer. Our research collaborations toward tests to reduce unnecessary biopsies and to distinguish indolent from aggressive cancer are ongoing.
More > |
|
Correlogic's technology has been successfully applied to various other cancers and conditions including colorectal cancer, Wegners disease, murine models, and experimental drug toxicity testing.
More > |
|
Correlogic’s technology has wide application beyond the medical context; these include financial market analysis, processing facilities, geographic surveys, weather stations, among others. We have published research suggesting our technology can provide a powerful tool for homeland security.
More > |
|